KLRK1 and gastric cancer: Kaedi Biotherapeutics designs a novel bispecific tandem CAR-T cells (KD-496), which targets both NKG2D ligands and Claudin 18.2 (CLDN18.2) to treat gastric cancer in vitro and in vivo (94).